Alpha Tau Medical’s Innovative Approach to Pancreatic Cancer Treatment: A Study Update

Alpha Tau Medical Ltd ((DRTS)) announced an update on their ongoing clinical study.

Alpha Tau Medical Ltd is conducting a clinical study titled A Study to Assess the Safety of Intratumoral Diffusing Alpha Radiation Emitters With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer. The study aims to evaluate the safety and efficacy of Alpha DaRT in combination with chemotherapy for treating pancreatic cancer. The primary focus is on assessing the safety of the treatment based on adverse events, while secondary objectives include evaluating overall survival, progression-free survival, pain control, and surgical resection rates.

The intervention being tested is the Diffusing Alpha Radiation Emitters Therapy (DaRT), a device designed to deliver targeted radiation therapy directly into the tumor. This approach aims to enhance the effectiveness of chemotherapy in treating pancreatic cancer.

The study is interventional, non-randomized, and open-label, with a parallel assignment model. It involves two cohorts of patients: those with locally advanced and those with metastatic pancreatic cancer. The primary purpose is treatment, with no masking involved.

The study began on June 17, 2025, and the last update was on August 13, 2025. These dates are crucial as they mark the study’s progress and the latest developments in the research.

This study update could positively impact Alpha Tau Medical’s stock performance by showcasing its commitment to innovative cancer treatments. Investors might view this as a promising development, potentially increasing interest in the company’s shares. In the competitive landscape of cancer treatment, advancements like these are critical for maintaining a competitive edge.

The study is ongoing, and further details can be found on the ClinicalTrials portal.